{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:42:35Z","timestamp":1774010555008,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["IRCT20191005044984N1"],"award-info":[{"award-number":["IRCT20191005044984N1"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-023-00470-2","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T08:02:01Z","timestamp":1691136121000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Golbarg","family":"Alavian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4235-6969","authenticated-orcid":false,"given":"Ladan","family":"Abbasian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ahmad Seyed","family":"Alinaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malihe","family":"Hasannezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh Farrokh","family":"Ashtiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ali Dehghan","family":"Manshadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"470_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831. https:\/\/doi.org\/10.3389\/fphar.2017.00831.","journal-title":"Front Pharmacol"},{"issue":"1","key":"470_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11904-018-0371-6","volume":"15","author":"BR De Miguel","year":"2018","unstructured":"De Miguel BR, Montejano R, Stella-Ascariz N, Arribas JR. New strategies of ARV: the road to simplification. Curr HIV\/AIDS Rep. 2018;15(1):11\u20139. https:\/\/doi.org\/10.1007\/s11904-018-0371-6.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"470_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/157488412800228910","volume":"7","author":"H Khalili","year":"2012","unstructured":"Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to Antiretroviral therapy among Iranian HIV\/AIDS Patients. Curr Clin Pharmacol. 2012;7:111\u20135. https:\/\/doi.org\/10.2174\/157488412800228910.","journal-title":"Curr Clin Pharmacol"},{"key":"470_CR4","first-page":"477","volume":"5","author":"A Moradi","year":"2016","unstructured":"Moradi A, Alavi SM, Fahim far N, Haghighizadeh MH, Mirzaei B. Study of determinants of adherence to antiretroviral treatment among HIV Patients covered by Ahwaz Jundishapur University of Medical Sciences. Int J Med Res Health Sci. 2016;5:477\u201384.","journal-title":"Int J Med Res Health Sci"},{"key":"470_CR5","first-page":"157","volume":"7","author":"A Bojdy","year":"2018","unstructured":"Bojdy A, Arian M, Najafi M, Mottaghi M. Adherence to antiretroviral therapy and its determinants in HIV patients in Mashhad, IRAN, a prospective study. Rev Clin Med. 2018;7:157\u201362.","journal-title":"Rev Clin Med"},{"key":"470_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13104-019-42045","volume":"12","author":"MA Morowatisharifabad","year":"2019","unstructured":"Morowatisharifabad MA, Movahed E, Farokhzadian J, Nikooie R, Hosseinzadeh M, Askarishahi M, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV\/AIDS: a case study in Iran. BMC Res Notes. 2019;12:162. https:\/\/doi.org\/10.1186\/s13104-019-42045.","journal-title":"BMC Res Notes"},{"key":"470_CR7","doi-asserted-by":"publisher","first-page":"232595821986732","DOI":"10.1177\/2325958219867325","volume":"18","author":"D Chastain","year":"2019","unstructured":"Chastain D, Badowski M, Huesgen E, Pandit NS, Pallotta A, Michienzi S. Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV practice and research network of the American College of clinical pharmacy. J Int Assoc Provid AIDS Care. 2019;18:2325958219867325. https:\/\/doi.org\/10.1177\/2325958219867325.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"470_CR8","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.2147\/DDDT.S140767","volume":"12","author":"KC Corado","year":"2018","unstructured":"Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of na\u00efve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018;12:3731\u201340. https:\/\/doi.org\/10.2147\/DDDT.S140767.","journal-title":"Drug Des Devel Ther"},{"key":"470_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40121-020-00290-w","volume":"9","author":"M Badowski","year":"2020","unstructured":"Badowski M, P\u00e9rez SE, Silva D, Lee A. Two\u2019s a company, three\u2019s a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-na\u00efve and treatment-experienced patients living with HIV-1. Infect Dis Ther. 2020;9:185\u2013208. https:\/\/doi.org\/10.1007\/s40121-020-00290-w.","journal-title":"Infect Dis Ther"},{"key":"470_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/QCO.0000000000000615","volume":"33","author":"L Waters","year":"2020","unstructured":"Waters L, Church H. Two drug regimens for HIV. Curr Opin Infect Dis. 2020;33:28\u201333. https:\/\/doi.org\/10.1097\/QCO.0000000000000615.","journal-title":"Curr Opin Infect Dis"},{"key":"470_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/phar.2246","volume":"39","author":"KM Brooks","year":"2019","unstructured":"Brooks KM, Sherman EM, Egelund EF, Brotherton A, Durham S, Badowski ME, et al. Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy. 2019;39:576\u201398. https:\/\/doi.org\/10.1002\/phar.2246.","journal-title":"Pharmacotherapy"},{"key":"470_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.12688\/f1000research.15995.2","volume":"7","author":"G Wandeler","year":"2018","unstructured":"Wandeler G, Buzzi M, Anderegg N, Sculier D, B\u00e9guelin C, Egger M, et al. Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. F1000Res. 2018;7:1359. https:\/\/doi.org\/10.12688\/f1000research.15995.2.","journal-title":"F1000Res"},{"key":"470_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/hiv.13050","volume":"22","author":"YS Punekar","year":"2021","unstructured":"Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22:423\u201333. https:\/\/doi.org\/10.1111\/hiv.13050.","journal-title":"HIV Med"},{"key":"470_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2022;36:39\u201348. https:\/\/doi.org\/10.1097\/QAD.0000000000003070.","journal-title":"AIDS"},{"key":"470_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12879-022-07769-6","volume":"22","author":"F Maggiolo","year":"2022","unstructured":"Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Cervo A, Valenti D, et al. Long-term outcome of lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2022;22:782. https:\/\/doi.org\/10.1186\/s12879-022-07769-6.","journal-title":"BMC Infect Dis"},{"key":"470_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/jac\/dkp141","volume":"64","author":"PM Girard","year":"2009","unstructured":"Girard PM, Cabi\u00e9 A, Michelet C, et al. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. J Anti microb Chemother. 2009;64:126\u201334.","journal-title":"J Anti microb Chemother"},{"key":"470_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4172\/jaa.1000024","volume":"2","author":"M Pinola","year":"2010","unstructured":"Pinola M, Lazzarin A, Antinori A, et al. Lopinavir\/ ritonavir? tenofovir dual therapy versus lopinavir\/ ritonavir-based triple therapy in HIV-infected antiretroviral na\u00efve subjects: the Kalead Study. J Antivir Antiretrovir. 2010;2:56\u201362. https:\/\/doi.org\/10.4172\/jaa.1000024.","journal-title":"J Antivir Antiretrovir"},{"key":"470_CR18","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231. https:\/\/doi.org\/10.1177\/2325958220919231.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"470_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","volume":"34","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34:2259\u201368. https:\/\/doi.org\/10.1097\/QAD.0000000000002699.","journal-title":"AIDS"},{"key":"470_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2174\/187152612804142251","volume":"12","author":"S Emamzadeh-Fard","year":"2012","unstructured":"Emamzadeh-Fard S, Fard SE. Author, Paydary K, Adherence to anti-retroviral therapy and its determinants in HIV\/AIDS patients: a review. Infect Disord Drug Targets. 2012;12:346\u201356. https:\/\/doi.org\/10.2174\/187152612804142251.","journal-title":"Infect Disord Drug Targets"},{"key":"470_CR21","unstructured":"https:\/\/eacs.sanfordguide.com\/art\/virological-failure. Accessed 8 Jan 2023."},{"key":"470_CR22","doi-asserted-by":"publisher","first-page":"e1003421","DOI":"10.1371\/journal.pmed.1003421","volume":"17","author":"D Sculier","year":"2020","unstructured":"Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL\u2019HIV trial. PLoS Med. 2020;17:e1003421. https:\/\/doi.org\/10.1371\/journal.pmed.1003421.","journal-title":"PLoS Med"},{"key":"470_CR23","doi-asserted-by":"publisher","first-page":"5923256","DOI":"10.1155\/2020\/5923256","volume":"7","author":"D Ward","year":"2020","unstructured":"Ward D, Ramgopal M, Riedel DJ, Garris C, Dhir S, Waller J, et al. Real-world experience with dolutegravir-based two-drug regimens. AIDS Res Treat. 2020;7:5923256. https:\/\/doi.org\/10.1155\/2020\/5923256.","journal-title":"AIDS Res Treat"},{"key":"470_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2215\/CJN.02240218","volume":"14","author":"MG Atta","year":"2019","unstructured":"Atta MG, De Seigneux S, Lucas GM. Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol. 2019;14:435\u201344. https:\/\/doi.org\/10.2215\/CJN.02240218.","journal-title":"Clin J Am Soc Nephrol"},{"key":"470_CR25","unstructured":"https:\/\/programme.aids2022.org\/PAGMaterial\/PPT\/3733_4919\/IAS_ADVANCE_W192POSTER_2022_AQ13JUL22.pdf. Accessed 10 Jan 2023."},{"key":"470_CR26","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24:e25702. https:\/\/doi.org\/10.1002\/jia2.25702.","journal-title":"J Int AIDS Soc"},{"key":"470_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/M20-4853","volume":"174","author":"B Surial","year":"2021","unstructured":"Surial B, Mugglin C, Calmy A, Cavassini M, G\u00fcnthard HF, St\u00f6ckle M, et al. Swiss HIV cohort study. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021;174:758\u201367. https:\/\/doi.org\/10.7326\/M20-4853.","journal-title":"Ann Intern Med"},{"key":"470_CR28","doi-asserted-by":"publisher","first-page":"e27047","DOI":"10.1097\/MD.0000000000027047","volume":"100","author":"J Darnell","year":"2021","unstructured":"Darnell J, Jain S, Sun X, Qin H, Reynolds T, Karris MY, et al. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. Medicine (Baltimore). 2021;100:e27047. https:\/\/doi.org\/10.1097\/MD.0000000000027047.","journal-title":"Medicine (Baltimore)"},{"key":"470_CR29","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","volume":"48","author":"S Kanters","year":"2022","unstructured":"Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. E Clin Med. 2022;48:101412. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101412.","journal-title":"E Clin Med"},{"key":"470_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.36469\/jheor.2022.31825","volume":"9","author":"B Emond","year":"2022","unstructured":"Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-world analysis of weight gain and body mass index increase among patients with HIV-1 using antiretroviral regimen containing tenofovir alafenamide, tenofovir disoproxil fumarate, or neither in the United States. J Health Econ Outcomes Res. 2022;9:39\u201349. https:\/\/doi.org\/10.36469\/jheor.2022.31825.","journal-title":"J Health Econ Outcomes Res."},{"key":"470_CR31","doi-asserted-by":"publisher","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","volume":"8","author":"BR Wood","year":"2021","unstructured":"Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis. 2021;8:ofab542.","journal-title":"Open Forum Infect Dis"},{"key":"470_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/AID.2019.0280.10.1093\/ofid\/ofab542","volume":"36","author":"V Petrakis","year":"2020","unstructured":"Petrakis V, Panagopoulos P, Papachristou S, Papanas N, Terzi I, Trypsianis G, et al. Tenofovir alafenamide fumarate therapy for HIV treatment: cardiometabolic and renal safety. AIDS Res Hum Retroviruses. 2020;36:697\u2013702. https:\/\/doi.org\/10.1089\/AID.2019.0280.10.1093\/ofid\/ofab542.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-023-00470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-023-00470-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-023-00470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:31:42Z","timestamp":1699003902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-023-00470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s40199-023-00470-2","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors have no any to declare regarding this submission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committees of Tehran University of Medical Sciences (IR.TUMS.TIPS.REC.1398.087).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}